The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read more here.

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

Despite the currency market anxiety, stocks pushed higher - with index futures adding to Thursday's Wall Street gains as the ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it ...